Mnemo Therapeutics locks in Series A

Mnemo Therapeutics, a provider of epigenetic antigens, stronger T cells, has raised 75 million euros in Series A funding.

16 June 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles